Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.64 Insider Own9.44% Shs Outstand64.39M Perf Week-0.65%
Market Cap195.75M Forward P/E- EPS next Y-0.64 Insider Trans1.09% Shs Float58.32M Perf Month3.75%
Income-38.07M PEG- EPS next Q-0.15 Inst Own47.28% Short Float2.44% Perf Quarter85.37%
Sales0.00M P/S- EPS this Y31.84% Inst Trans-1.73% Short Ratio4.24 Perf Half Y90.00%
Book/sh0.72 P/B4.20 EPS next Y-6.04% ROA-69.74% Short Interest1.43M Perf Year101.32%
Cash/sh0.77 P/C3.96 EPS next 5Y- ROE-80.42% 52W Range1.11 - 3.53 Perf YTD28.81%
Dividend Est.- P/FCF- EPS past 5Y4.69% ROI-81.32% 52W High-13.88% Beta2.18
Dividend TTM- Quick Ratio8.14 Sales past 5Y-45.53% Gross Margin-1282.66% 52W Low173.87% ATR (14)0.23
Dividend Ex-Date- Current Ratio8.14 EPS Y/Y TTM38.24% Oper. Margin0.00% RSI (14)51.29 Volatility5.69% 7.22%
Employees39 Debt/Eq0.02 Sales Y/Y TTM-100.00% Profit Margin- Recom1.25 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q12.05% Payout- Rel Volume0.58 Prev Close3.01
Sales Surprise- EPS Surprise2.30% Sales Q/Q- EarningsNov 03 BMO Avg Volume336.12K Price3.04
SMA20-1.20% SMA503.25% SMA20057.66% Trades Volume197,887 Change1.00%
Date Action Analyst Rating Change Price Target Change
Dec-22-23Initiated CapitalOne Overweight $12
Nov-12-21Upgrade Jefferies Hold → Buy $3 → $4
Nov-14-19Initiated ROTH Capital Buy $12
Aug-05-19Downgrade SunTrust Buy → Hold $23 → $5
Aug-05-19Downgrade Piper Jaffray Overweight → Neutral $20 → $6
Aug-05-19Downgrade Jefferies Buy → Hold
Apr-12-19Initiated Piper Jaffray Overweight $20
Dec-18-18Initiated H.C. Wainwright Buy $24
Jul-26-16Initiated SunTrust Buy
Mar-17-15Reiterated Stifel Buy $13 → $14
Feb-26-24 07:00AM
Feb-12-24 07:00AM
Jan-04-24 07:00AM
Jan-03-24 07:00AM
Dec-10-23 12:00PM
07:00AM Loading…
Nov-09-23 07:00AM
Nov-05-23 08:51AM
Nov-04-23 01:48AM
Nov-03-23 10:33AM
Oct-23-23 08:30AM
Oct-20-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:00AM
07:00AM Loading…
Aug-17-23 07:00AM
Aug-02-23 07:17AM
Jul-19-23 07:00AM
Jul-13-23 09:29AM
Jun-26-23 08:00AM
Jun-15-23 08:00AM
Jun-12-23 11:13AM
May-31-23 07:00AM
May-16-23 10:37AM
May-03-23 10:17PM
Apr-26-23 07:00AM
Apr-19-23 10:20AM
01:45PM Loading…
Apr-05-23 01:45PM
Mar-31-23 04:30AM
Mar-29-23 07:00AM
Mar-21-23 06:23AM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 07:00AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 07:00AM
Feb-28-23 06:43AM
Feb-27-23 06:50AM
Feb-24-23 07:17AM
Feb-16-23 08:00AM
Feb-15-23 08:00AM
Feb-14-23 06:23AM
Feb-06-23 07:00AM
Jan-22-23 07:30AM
Dec-30-22 07:17AM
Dec-28-22 06:58AM
Dec-26-22 07:14AM
Dec-19-22 09:40AM
Dec-12-22 07:00AM
Dec-02-22 01:18PM
Nov-23-22 09:55AM
Nov-16-22 09:40AM
Nov-12-22 07:14AM
Nov-10-22 09:12AM
Nov-09-22 07:00AM
Nov-08-22 04:05PM
Nov-03-22 09:00AM
Nov-02-22 07:00AM
Oct-10-22 11:57PM
Oct-04-22 12:00PM
Sep-09-22 08:30AM
Sep-07-22 07:00AM
Sep-06-22 07:00AM
Aug-09-22 12:00PM
Aug-03-22 02:00PM
Jul-27-22 04:00PM
Jul-18-22 10:22AM
Jun-03-22 08:36AM
Jun-02-22 04:00PM
Apr-28-22 06:30PM
Apr-25-22 09:00AM
Mar-08-22 04:30PM
Mar-03-22 04:15PM
Mar-02-22 09:15AM
Feb-25-22 09:00AM
Feb-23-22 04:30PM
Dec-13-21 09:00AM
Dec-06-21 09:15AM
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rock EdwinChief Medical OfficerSep 22Buy1.3830,40341,956375,403Sep 25 04:21 PM
Rock EdwinChief Medical OfficerSep 21Buy1.3835,00048,300345,000Sep 25 04:21 PM
Koenig ScottDirectorJun 01Option Exercise0.6021,00012,60036,750Jun 02 04:10 PM
Hahn Brian M.SVP Finance, CFOMay 17Sale1.953,7007,21553,143May 18 04:27 PM
JUNIUS DANIEL MDirectorMay 10Buy1.5630,00046,80093,250May 11 05:08 PM
Johnson Bruce SSVP & Chief Commercial OfficerMay 08Buy1.5713,50021,195138,980May 09 05:00 PM